| Effect of weight reduction on hepatic abnormalities in overweight patients M Palmer, F Schaffner Gastroenterology 99 (5), 1408-1413, 1990 | 504 | 1990 |
| A phase 2, randomized, double‐blind, placebo‐controlled study of GS‐9450 in subjects with nonalcoholic steatohepatitis V Ratziu, MY Sheikh, AJ Sanyal, JK Lim, H Conjeevaram, N Chalasani, ... Hepatology 55 (2), 419-428, 2012 | 195 | 2012 |
| Global multi-stakeholder endorsement of the MAFLD definition N Méndez-Sánchez, E Bugianesi, RG Gish, F Lammert, H Tilg, ... The lancet Gastroenterology & hepatology 7 (5), 388-390, 2022 | 166 | 2022 |
| Excessive weight gain after liver transplantation M PALMER, F SCHAFFNER, SN THUNG Transplantation 51 (4), 797-800, 1991 | 112 | 1991 |
| Outcome of primary sclerosing cholangitis: analysis of long-term observation of 38 patients E Lebovics, M Palmer, J Woo, F Schaffner Archives of internal medicine 147 (4), 729-731, 1987 | 75 | 1987 |
| Equipotent inhibition by R (−)−, S (+)‐and racemic ibuprofen of human polymorphonuclear cell function in vitro. M Villanueva, R Heckenberger, H Strobach, M Palmer, K Schror British journal of clinical pharmacology 35 (3), 235-242, 1993 | 72 | 1993 |
| Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study PN Newsome, M Palmer, B Freilich, MY Sheikh, A Sheikh, H Sarles, ... Journal of hepatology 73 (2), 231-240, 2020 | 56 | 2020 |
| Prediction of survival of patients with primary biliary cirrhosis: examination of the Mayo clinic model on a group of patients with known endpoint FM Klion, TL Fabry, M Palmer, F Schaffner Gastroenterology 102 (1), 310-313, 1992 | 56 | 1992 |
| Apical sodium-dependent bile acid transporter inhibition with volixibat improves metabolic aspects and components of non-alcoholic steatohepatitis in Ldlr-/-. Leiden mice K Salic, R Kleemann, C Wilkins-Port, J McNulty, L Verschuren, M Palmer PLoS One 14 (6), e0218459, 2019 | 47 | 2019 |
| Dr. Melissa Palmer's Guide To Hepatitis and Liver Disease: A Practical Guide to Understanding, Treating & Living with Hepatitis & Liver M Palmer Penguin, 2004 | 45 | 2004 |
| Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes … RG Tiessen, CA Kennedy, BT Keller, N Levin, L Acevedo, B Gedulin, ... BMC gastroenterology 18, 1-17, 2018 | 42 | 2018 |
| Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug‐induced liver injury during clinical trials in patients with nonalcoholic … A Regev, M Palmer, MI Avigan, L Dimick‐Santos, WR Treem, JF Marcinak, ... Alimentary pharmacology & therapeutics 49 (6), 702-713, 2019 | 33 | 2019 |
| SEOM clinical guidelines in advanced and recurrent breast cancer (2018) JI Chacón López-Muñiz, L de la Cruz Merino, J Gavilá Gregori, ... Clinical and Translational Oncology 21, 31-45, 2019 | 30 | 2019 |
| A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults … M Palmer, L Jennings, DG Silberg, C Bliss, P Martin BMC Pharmacology and Toxicology 19, 1-13, 2018 | 27 | 2018 |
| Consensus guidelines: best practices for detection, assessment and management of suspected acute drug‐induced liver injury occurring during clinical trials in adults with … M Palmer, A Regev, K Lindor, MI Avigan, L Dimick‐Santos, W Treem, ... Alimentary Pharmacology & Therapeutics 51 (1), 90-109, 2020 | 26 | 2020 |
| Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in adults with chronic viral … WR Treem, M Palmer, I Lonjon-Domanec, D Seekins, L Dimick-Santos, ... Drug Safety 44, 133-165, 2021 | 25 | 2021 |
| Documento de consenso JÁ Hernández, DM Carmona, MP Vila, IR Rodríguez, PS Rovira, ... Nutrición Hospitalaria 1 (1), 13-48, 2008 | 24 | 2008 |
| Duration of shedding of Verocytotoxin-producing Escherichia coli in children and risk of transmission in childcare facilities in England G Dabke, A Le Menach, A Black, J Gamblin, M Palmer, N Boxall, L Booth Epidemiology & Infection 142 (2), 327-334, 2014 | 23 | 2014 |
| Absorption, Distribution, Metabolism, and Excretion of [14C]-Volixibat in Healthy Men: Phase 1 Open-Label Study N Siebers, M Palmer, DG Silberg, L Jennings, C Bliss, PT Martin European Journal of Drug Metabolism and Pharmacokinetics 43, 91-101, 2018 | 18 | 2018 |
| The liver in acquired immune deficiency disease M Palmer, LF Braly, F Schaffner Seminars in Liver Disease 7 (03), 192-202, 1987 | 17 | 1987 |
